|
¼ÅÇѤ«Õ¹àÍ´ÊìµÔ´Íѹ´Ñº 2 ¡ÒûÃдÔɰì¤Ô´¤é¹ÂÔè§ãËè´éÒ¹¡ÒÃá¾·ÂìáËè§»Õ 2552
(¨Ñ´Íѹ´Ñºâ´Â¹ÔµÂÊÒà TIME)
¹ÔµÂÊÒà TIME ÊÃØ»¤ÇÒÁ¡éÒÇ˹éÒ´éÒ¹ÇÔ·ÂÒ¡ÒÃã¹Ãͺ»Õ 2552 áÅеվÔÁ¾ìà¼Âá¾ÃèàÁ×èÍÇѹ·Õè 23 ¾ÄȨԡÒ¹ 2552 ¼Å¡ÒäѴàÅ×Í¡ 50 Íѹ´Ñºáá¢Í§âÅ¡ ÁռšÒÃÇÔ¨ÑÂÇѤ«Õ¹àÍ´Êì·Õè»éͧ¡Ñ¹¡ÒõԴàª×éÍä´é 31.2% ¤ÃÑé§¹Õéà»ç¹Íѹ´Ñº·Õè 2 㹡Òä鹾º´éÒ¹¡ÒÃá¾·Âì áÅÐà»ç¹Íѹ´Ñº 8 㹡Òä鹾ºÃÇÁ·Ø¡àÃ×èͧ
¹Í¡¨Ò¡¹Õé ¨Ò¡¡ÒÃãËé¼Ùéà¢éÒªÁàÇçºä«µì¢Í§ TIME ãËé¤Ðá¹¹¤ÇÒÁÊÓ¤ÑáµèÅÐàÃ×èͧ áÅÐÇѤ«Õ¹àÍ´Êìä´éÃѺ¤Ðá¹¹¤ÇÒÁÊÓ¤Ñà»ç¹Íѹ´Ñº 5
¤Åԡ仪Á·ÕèàÇ红ͧ¹ÔµÊÒà TIME www.time.com/ |
IAVI Report ÃÒ§ҹ»ÃÐà´ç¹ÊӤѼšÒÃÈÖ¡ÉÒÇѤ«Õ¹
ÁÕ¡ÒùÓàʹÍá¹Çâ¹éÁ»ÃÐÊÔ·¸Ô¼ÅÇѤ«Õ¹«Öè§à»ç¹¡ÒÃÇÔà¤ÃÒÐËì¡ÅØèÁÂèÍ ·Õè·ÓãËéà¡Ô´ÊÁÁµÔ°Ò¹ÇèÒ ÃдѺÀÙÁÔ¤ØéÁ¡Ñ¹¢Öé¹ÊÙ§ã¹»ÕáááÅÐŴŧËÅѧ¨Ò¡¹Ñé¹ ÃÇÁ·Ñé§¡ÒÃáÊ´§¼Å¢Í§ÇѤ«Õ¹·ÕèÍÒ¨¨ÐᵡµèÒ§¡Ñ¹ã¹¡ÅØèÁ»ÃЪҡ÷ÕèÁÕ¤ÇÒÁàÊÕè§ᵡµèÒ§¡Ñ¹ (¤ÅÔ¡ÃÙ»à¾×èÍÍèÒ¹ÃÒÂÅÐàÍÕ´)
........................................................................................
As 2009, what has been referred to as a banner year in AIDS vaccine research and development draws to a close, there are many exciting advances to highlight and reflect upon. Not the least of these was the first hint of vaccine-induced protection against HIV infection to emerge from a clinical trial. The 16,000-person RV144 trial in Thailand brought unexpected results the prime-boost regimen many researchers in the field had all but written off, provided a modest but statistically significant 31% protection against HIV infection.(Click at the picture for details) |